5.92
-0.02(-0.34%)
Currency In USD
| Previous Close | 5.94 |
| Open | 5.97 |
| Day High | 6.05 |
| Day Low | 5.51 |
| 52-Week High | 7.31 |
| 52-Week Low | 1.31 |
| Volume | 206,567 |
| Average Volume | 174,706 |
| Market Cap | 125.74M |
| PE | -0.55 |
| EPS | -10.85 |
| Moving Average 50 Days | 4.24 |
| Moving Average 200 Days | 2.8 |
| Change | -0.02 |
If you invested $1000 in CAMP4 Therapeutics Corporation (CAMP) since IPO date, it would be worth $552.24 as of December 24, 2025 at a share price of $5.92. Whereas If you bought $1000 worth of CAMP4 Therapeutics Corporation (CAMP) shares 6 months ago, it would be worth $3,587.88 as of December 24, 2025 at a share price of $5.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
Dec 18, 2025 12:10 PM GMT
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upre
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments,
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 12, 2025 9:05 PM GMT
CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upre